178 related articles for article (PubMed ID: 32880085)
1. Adenosine Deaminase (ADA)-Deficient Severe Combined Immune Deficiency (SCID) in the US Immunodeficiency Network (USIDNet) Registry.
Kuo CY; Garabedian E; Puck J; Cowan MJ; Sullivan KE; Buckley RH; Cunningham-Rundles C; Marsh R; Candotti F; Kohn DB
J Clin Immunol; 2020 Nov; 40(8):1124-1131. PubMed ID: 32880085
[TBL] [Abstract][Full Text] [Related]
2. How We Manage Adenosine Deaminase-Deficient Severe Combined Immune Deficiency (ADA SCID).
Kohn DB; Gaspar HB
J Clin Immunol; 2017 May; 37(4):351-356. PubMed ID: 28194615
[TBL] [Abstract][Full Text] [Related]
3. ADA Deficiency: Evaluation of the Clinical and Laboratory Features and the Outcome.
Cagdas D; Gur Cetinkaya P; Karaatmaca B; Esenboga S; Tan C; Yılmaz T; Gümüş E; Barış S; Kuşkonmaz B; Ozgur TT; Bali P; Santisteban I; Orhan D; Yüce A; Cetinkaya D; Boztug K; Hershfield M; Sanal O; Tezcan İ
J Clin Immunol; 2018 May; 38(4):484-493. PubMed ID: 29744787
[TBL] [Abstract][Full Text] [Related]
4. Consensus approach for the management of severe combined immune deficiency caused by adenosine deaminase deficiency.
Kohn DB; Hershfield MS; Puck JM; Aiuti A; Blincoe A; Gaspar HB; Notarangelo LD; Grunebaum E
J Allergy Clin Immunol; 2019 Mar; 143(3):852-863. PubMed ID: 30194989
[TBL] [Abstract][Full Text] [Related]
5. Long-Term Outcome of Adenosine Deaminase-Deficient Patients-a Single-Center Experience.
Scott O; Kim VH; Reid B; Pham-Huy A; Atkinson AR; Aiuti A; Grunebaum E
J Clin Immunol; 2017 Aug; 37(6):582-591. PubMed ID: 28748310
[TBL] [Abstract][Full Text] [Related]
6. Clinical efficacy of gene-modified stem cells in adenosine deaminase-deficient immunodeficiency.
Shaw KL; Garabedian E; Mishra S; Barman P; Davila A; Carbonaro D; Shupien S; Silvin C; Geiger S; Nowicki B; Smogorzewska EM; Brown B; Wang X; de Oliveira S; Choi Y; Ikeda A; Terrazas D; Fu PY; Yu A; Fernandez BC; Cooper AR; Engel B; Podsakoff G; Balamurugan A; Anderson S; Muul L; Jagadeesh GJ; Kapoor N; Tse J; Moore TB; Purdy K; Rishi R; Mohan K; Skoda-Smith S; Buchbinder D; Abraham RS; Scharenberg A; Yang OO; Cornetta K; Gjertson D; Hershfield M; Sokolic R; Candotti F; Kohn DB
J Clin Invest; 2017 May; 127(5):1689-1699. PubMed ID: 28346229
[TBL] [Abstract][Full Text] [Related]
7. Hematopoietic stem cell gene therapy for adenosine deaminase-deficient severe combined immunodeficiency leads to long-term immunological recovery and metabolic correction.
Gaspar HB; Cooray S; Gilmour KC; Parsley KL; Zhang F; Adams S; Bjorkegren E; Bayford J; Brown L; Davies EG; Veys P; Fairbanks L; Bordon V; Petropoulou T; Kinnon C; Thrasher AJ
Sci Transl Med; 2011 Aug; 3(97):97ra80. PubMed ID: 21865538
[TBL] [Abstract][Full Text] [Related]
8. Hematopoietic Cell Transplantation for Adenosine Deaminase Severe Combined Immunodeficiency-Improved Outcomes in the Modern Era.
Ghimenton E; Flinn A; Lum SH; Leahy TR; Nademi Z; Owens S; Williams E; Flood T; Hambleton S; Slatter M; Gennery AR
J Clin Immunol; 2022 May; 42(4):819-826. PubMed ID: 35288820
[TBL] [Abstract][Full Text] [Related]
9. National experience with adenosine deaminase deficiency related SCID in Polish children.
Dąbrowska-Leonik N; Piątosa B; Słomińska E; Bohynikova N; Bernat-Sitarz K; Bernatowska E; Wolska-Kuśnierz B; Kałwak K; Kołtan S; Dąbrowska A; Goździk J; Ussowicz M; Pac M
Front Immunol; 2022; 13():1058623. PubMed ID: 36685585
[TBL] [Abstract][Full Text] [Related]
10. Long-term outcomes after gene therapy for adenosine deaminase severe combined immune deficiency.
Reinhardt B; Habib O; Shaw KL; Garabedian E; Carbonaro-Sarracino DA; Terrazas D; Fernandez BC; De Oliveira S; Moore TB; Ikeda AK; Engel BC; Podsakoff GM; Hollis RP; Fernandes A; Jackson C; Shupien S; Mishra S; Davila A; Mottahedeh J; Vitomirov A; Meng W; Rosenfeld AM; Roche AM; Hokama P; Reddy S; Everett J; Wang X; Luning Prak ET; Cornetta K; Hershfield MS; Sokolic R; De Ravin SS; Malech HL; Bushman FD; Candotti F; Kohn DB
Blood; 2021 Oct; 138(15):1304-1316. PubMed ID: 33974038
[TBL] [Abstract][Full Text] [Related]
11. Update on the safety and efficacy of retroviral gene therapy for immunodeficiency due to adenosine deaminase deficiency.
Cicalese MP; Ferrua F; Castagnaro L; Pajno R; Barzaghi F; Giannelli S; Dionisio F; Brigida I; Bonopane M; Casiraghi M; Tabucchi A; Carlucci F; Grunebaum E; Adeli M; Bredius RG; Puck JM; Stepensky P; Tezcan I; Rolfe K; De Boever E; Reinhardt RR; Appleby J; Ciceri F; Roncarolo MG; Aiuti A
Blood; 2016 Jul; 128(1):45-54. PubMed ID: 27129325
[TBL] [Abstract][Full Text] [Related]
12. Infections in Infants with SCID: Isolation, Infection Screening, and Prophylaxis in PIDTC Centers.
Dorsey MJ; Wright NAM; Chaimowitz NS; Dávila Saldaña BJ; Miller H; Keller MD; Thakar MS; Shah AJ; Abu-Arja R; Andolina J; Aquino V; Barnum JL; Bednarski JJ; Bhatia M; Bonilla FA; Butte MJ; Bunin NJ; Chandra S; Chaudhury S; Chen K; Chong H; Cuvelier GDE; Dalal J; DeFelice ML; DeSantes KB; Forbes LR; Gillio A; Goldman F; Joshi AY; Kapoor N; Knutsen AP; Kobrynski L; Lieberman JA; Leiding JW; Oshrine B; Patel KP; Prockop S; Quigg TC; Quinones R; Schultz KR; Seroogy C; Shyr D; Siegel S; Smith AR; Torgerson TR; Vander Lugt MT; Yu LC; Cowan MJ; Buckley RH; Dvorak CC; Griffith LM; Haddad E; Kohn DB; Logan B; Notarangelo LD; Pai SY; Puck J; Pulsipher MA; Heimall J
J Clin Immunol; 2021 Jan; 41(1):38-50. PubMed ID: 33006109
[TBL] [Abstract][Full Text] [Related]
13. First Occurrence of Plasmablastic Lymphoma in Adenosine Deaminase-Deficient Severe Combined Immunodeficiency Disease Patient and Review of the Literature.
Migliavacca M; Assanelli A; Ponzoni M; Pajno R; Barzaghi F; Giglio F; Ferrua F; Frittoli M; Brigida I; Dionisio F; Nicoletti R; Casiraghi M; Roncarolo MG; Doglioni C; Peccatori J; Ciceri F; Cicalese MP; Aiuti A
Front Immunol; 2018; 9():113. PubMed ID: 29456531
[TBL] [Abstract][Full Text] [Related]
14. Autologous Ex Vivo Lentiviral Gene Therapy for Adenosine Deaminase Deficiency.
Kohn DB; Booth C; Shaw KL; Xu-Bayford J; Garabedian E; Trevisan V; Carbonaro-Sarracino DA; Soni K; Terrazas D; Snell K; Ikeda A; Leon-Rico D; Moore TB; Buckland KF; Shah AJ; Gilmour KC; De Oliveira S; Rivat C; Crooks GM; Izotova N; Tse J; Adams S; Shupien S; Ricketts H; Davila A; Uzowuru C; Icreverzi A; Barman P; Campo Fernandez B; Hollis RP; Coronel M; Yu A; Chun KM; Casas CE; Zhang R; Arduini S; Lynn F; Kudari M; Spezzi A; Zahn M; Heimke R; Labik I; Parrott R; Buckley RH; Reeves L; Cornetta K; Sokolic R; Hershfield M; Schmidt M; Candotti F; Malech HL; Thrasher AJ; Gaspar HB
N Engl J Med; 2021 May; 384(21):2002-2013. PubMed ID: 33974366
[TBL] [Abstract][Full Text] [Related]
15. Adenosine Deaminase (ADA)-Deficient Severe Combined Immune Deficiency (SCID): Molecular Pathogenesis and Clinical Manifestations.
Bradford KL; Moretti FA; Carbonaro-Sarracino DA; Gaspar HB; Kohn DB
J Clin Immunol; 2017 Oct; 37(7):626-637. PubMed ID: 28842866
[TBL] [Abstract][Full Text] [Related]
16. Patients with adenosine deaminase deficiency surviving after hematopoietic stem cell transplantation are at high risk of CNS complications.
Hönig M; Albert MH; Schulz A; Sparber-Sauer M; Schütz C; Belohradsky B; Güngör T; Rojewski MT; Bode H; Pannicke U; Lippold D; Schwarz K; Debatin KM; Hershfield MS; Friedrich W
Blood; 2007 Apr; 109(8):3595-602. PubMed ID: 17185467
[TBL] [Abstract][Full Text] [Related]
17. Twenty-Five Years of Gene Therapy for ADA-SCID: From Bubble Babies to an Approved Drug.
Ferrua F; Aiuti A
Hum Gene Ther; 2017 Nov; 28(11):972-981. PubMed ID: 28847159
[TBL] [Abstract][Full Text] [Related]
18. Gene therapy for immunodeficiency due to adenosine deaminase deficiency.
Aiuti A; Cattaneo F; Galimberti S; Benninghoff U; Cassani B; Callegaro L; Scaramuzza S; Andolfi G; Mirolo M; Brigida I; Tabucchi A; Carlucci F; Eibl M; Aker M; Slavin S; Al-Mousa H; Al Ghonaium A; Ferster A; Duppenthaler A; Notarangelo L; Wintergerst U; Buckley RH; Bregni M; Marktel S; Valsecchi MG; Rossi P; Ciceri F; Miniero R; Bordignon C; Roncarolo MG
N Engl J Med; 2009 Jan; 360(5):447-58. PubMed ID: 19179314
[TBL] [Abstract][Full Text] [Related]
19. Treatment with Elapegademase Restores Immunity in Infants with Adenosine Deaminase Deficient Severe Combined Immunodeficiency.
Hicks ED; Hall G; Hershfield MS; Tarrant TK; Bali P; Sleasman JW; Buckley RH; Mousallem T
J Clin Immunol; 2024 Apr; 44(5):107. PubMed ID: 38676811
[TBL] [Abstract][Full Text] [Related]
20. Outcomes following treatment for ADA-deficient severe combined immunodeficiency: a report from the PIDTC.
Cuvelier GDE; Logan BR; Prockop SE; Buckley RH; Kuo CY; Griffith LM; Liu X; Yip A; Hershfield MS; Ayoub PG; Moore TB; Dorsey MJ; O'Reilly RJ; Kapoor N; Pai SY; Kapadia M; Ebens CL; Forbes Satter LR; Burroughs LM; Petrovic A; Chellapandian D; Heimall J; Shyr DC; Rayes A; Bednarski JJ; Chandra S; Chandrakasan S; Gillio AP; Madden L; Quigg TC; Caywood EH; Dávila Saldaña BJ; DeSantes K; Eissa H; Goldman FD; Rozmus J; Shah AJ; Vander Lugt MT; Thakar MS; Parrott RE; Martinez C; Leiding JW; Torgerson TR; Pulsipher MA; Notarangelo LD; Cowan MJ; Dvorak CC; Haddad E; Puck JM; Kohn DB
Blood; 2022 Aug; 140(7):685-705. PubMed ID: 35671392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
